Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Sep 12;396(10253):741-743.
doi: 10.1016/S0140-6736(20)31821-3. Epub 2020 Aug 27.

COVID-19 vaccine trials should seek worthwhile efficacy

Philip Krause  1 , Thomas R Fleming  2 , Ira Longini  3 , Ana Maria Henao-Restrepo  4 , Richard Peto  5 ; World Health Organization Solidarity Vaccines Trial Expert Group
Collaborators, Affiliations

COVID-19 vaccine trials should seek worthwhile efficacy

Philip Krause et al. Lancet. .
No abstract available

PubMed Disclaimer

Figures

Figure
Figure
Selected design features of the WHO Solidarity Vaccines Trial The primary outcome is laboratory-confirmed symptoms >14 days after vaccination is completed. Analyses of each vaccine after about 40, 70, and 100 primary outcomes occur in the placebo group will report success if they show ≤10 versus 40, ≤30 versus 70, or ≤50 versus 100 outcomes. The third analysis is reported regardless of its findings. In all cases placebo-controlled follow-up continues until at least month 12 (or local deployment of an effective vaccine) to assess safety, disease severity, and duration of protection.
See this image and copyright information in PMC

References

    1. Fleming TR. Current issues in non-inferiority trials. Stat Med. 2008;27:317–332. - PubMed
    1. WHO Draft landscape of COVID-19 candidate vaccines, 2020. Aug 25, 2020. https://www.who.int/publications/m/item/draft-landscape-of-covid-19-cand...
    1. WHO WHO target product profiles for COVID-19 vaccines. April 9, 2020. https://www.who.int/who-documents-detail/who-target-product-profiles-for...
    1. US Food and Drug Administration Development and licensure of vaccines to prevent COVID-19: guidance for industry. June, 2020. https://www.fda.gov/regulatory-information/search-fda-guidance-documents...
    1. Hotez PJ, Corry DB, Bottazzi ME. COVID-19 vaccine design: the Janus face of immune enhancement. Nat Rev Immunol. 2020;20:347–348. - PMC - PubMed

MeSH terms